|
Volumn 8, Issue 11, 2013, Pages 1350-1351
|
Lung cancer - Celebrating progress and acknowledging challenges
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AGATOLIMOD;
ANTINEOPLASTIC AGENT;
APRINOCARSEN;
BEXAROTENE;
FIGITUMUMAB;
HEAT SHOCK PROTEIN 90 INHIBITOR;
LONAFARNIB;
PRINOMASTAT;
PROGRAMMED CELL DEATH 1 ANTIBODY;
PROGRAMMED CELL DEATH LIGAND 1 ANTIBODY;
SORAFENIB;
TALACTOFERRIN;
TIVANTINIB;
UNCLASSIFIED DRUG;
VADIMEZAN;
CANCER INCIDENCE;
CANCER MORTALITY;
CANCER PREVENTION;
CANCER RISK;
CANCER SCREENING;
CAUSAL ATTRIBUTION;
CLINICAL RESEARCH;
COMPUTER ASSISTED TOMOGRAPHY;
COST EFFECTIVENESS ANALYSIS;
EDITORIAL;
GENE AMPLIFICATION;
GENE MUTATION;
GENE SEQUENCE;
GOVERNMENT;
HEALTH CARE SYSTEM;
HUMAN;
IMMUNOMODULATION;
INTERMETHOD COMPARISON;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
MEDICAL SOCIETY;
ONCOGENE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PREVALENCE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SMOKING;
SMOKING CESSATION;
THORAX RADIOGRAPHY;
TREATMENT RESPONSE;
TUMOR SUPPRESSOR GENE;
HUMANS;
LUNG NEOPLASMS;
|
EID: 84886547017
PISSN: 15560864
EISSN: 15561380
Source Type: Journal
DOI: 10.1097/JTO.0000000000000008 Document Type: Editorial |
Times cited : (2)
|
References (9)
|